Scholarlink

Background <p>The introduction of genetic tests based on next-generation sequencing techniques into veterinary cancer diagnostics provides information on molecularly targeted therapies useful for dogs. However, there is still a lack of in vitro studies describing the effect and mechanism of action of such anti-cancer drugs in companion animals. Our study aimed to demonstrate in vitro activity of a commonly used PARP inhibitor, olaparib, in canine lymphoma and leukemia cells as well as to indicate its potential uses in anti-cancer therapy based on the mutational status of DNA damage related genes. Canine lymphoma and leukemia cell lines were incubated with olaparib alone and in combination with doxorubicin, and the impact of a single drug and combinations on cell viability, proliferation, induction of apoptosis, and DNA damage were assessed.</p> Results <p>The study showed that olaparib acts as a single agent, inhibiting the metabolic activity of canine lymphoma (CLBL-1, CNK-89) and leukemia (CLB70, GL-1) cells, affecting cell proliferation rates and causing DNA damage. In the tested cells, olaparib also worked as a chemosensitizer, due to its ability to potentiate cytotoxic effects of doxorubicin. Finally, RNA-seq data identify various mutational burden differences in genes involved in the DNA damage response in CLBL-1 and GL-1 cell lines that may explain the observed in vitro sensitivity differences to olaparib.</p> Conclusions <p>Olaparib may be an interesting oral therapy alternative to classic chemotherapy or adjuvant option in dogs with hematopoietic cancer with known DNA repair disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月5日

查看全文
  • Jayson Cagadas Pasaol,
  • Ewa Dejnaka,
  • Greta Mucignat,
  • Joanna Bajzert,
  • Marta Henklewska,
  • Bożena Obmińska-Mrukowicz,
  • Mery Giantin,
  • Marianna Pauletto,
  • Christopher Zdyrski,
  • Mauro Dacasto,
  • Aleksandra Pawlak

摘要

Background

The introduction of genetic tests based on next-generation sequencing techniques into veterinary cancer diagnostics provides information on molecularly targeted therapies useful for dogs. However, there is still a lack of in vitro studies describing the effect and mechanism of action of such anti-cancer drugs in companion animals. Our study aimed to demonstrate in vitro activity of a commonly used PARP inhibitor, olaparib, in canine lymphoma and leukemia cells as well as to indicate its potential uses in anti-cancer therapy based on the mutational status of DNA damage related genes. Canine lymphoma and leukemia cell lines were incubated with olaparib alone and in combination with doxorubicin, and the impact of a single drug and combinations on cell viability, proliferation, induction of apoptosis, and DNA damage were assessed.

Results

The study showed that olaparib acts as a single agent, inhibiting the metabolic activity of canine lymphoma (CLBL-1, CNK-89) and leukemia (CLB70, GL-1) cells, affecting cell proliferation rates and causing DNA damage. In the tested cells, olaparib also worked as a chemosensitizer, due to its ability to potentiate cytotoxic effects of doxorubicin. Finally, RNA-seq data identify various mutational burden differences in genes involved in the DNA damage response in CLBL-1 and GL-1 cell lines that may explain the observed in vitro sensitivity differences to olaparib.

Conclusions

Olaparib may be an interesting oral therapy alternative to classic chemotherapy or adjuvant option in dogs with hematopoietic cancer with known DNA repair disorders.